Ocular TherapeutixOCUL
OCUL
About: Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Employees: 267
0
Funds holding %
of 6,790 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
106% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 17
43% more funds holding in top 10
Funds holding in top 10: 7 [Q2] → 10 (+3) [Q3]
23% more capital invested
Capital invested by funds: $989M [Q2] → $1.22B (+$230M) [Q3]
12% more funds holding
Funds holding: 149 [Q2] → 167 (+18) [Q3]
3.64% less ownership
Funds ownership: 93.4% [Q2] → 89.76% (-3.64%) [Q3]
16% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 49
26% less call options, than puts
Call options by funds: $2.34M | Put options by funds: $3.17M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$14
51%
upside
Avg. target
$16.50
78%
upside
High target
$22
137%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen 49% 1-year accuracy 54 / 110 met price target | 62%upside $15 | Buy Reiterated | 3 Dec 2024 |
HC Wainwright & Co. Yi Chen 49% 1-year accuracy 54 / 110 met price target | 62%upside $15 | Buy Maintained | 15 Nov 2024 |
Scotiabank Greg Harrison 43% 1-year accuracy 6 / 14 met price target | 137%upside $22 | Sector Outperform Initiated | 16 Oct 2024 |
HC Wainwright & Co. Yi Chen 49% 1-year accuracy 54 / 110 met price target | 51%upside $14 | Buy Reiterated | 16 Oct 2024 |
Financial journalist opinion
Based on 6 articles about OCUL published over the past 30 days
Neutral
GlobeNewsWire
3 days ago
Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1
SOL-1 is the first registrational trial for AXPAXLI™ in wet AMD Topline clinical data from SOL-1 expected in Q4 2025 Active clinical trial sites enrolling patients directly into second registrational trial, SOL-R, while additional sites continue to be activated BEDFORD, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that more than 300 patients have been randomized in the SOL-1 Phase 3 trial for AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), and the trial is expected to close randomization this week.
Neutral
GlobeNewsWire
1 week ago
Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences
BEDFORD, Mass. , Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced participation in several investor and scientific conferences being held in December.
Neutral
Seeking Alpha
3 weeks ago
Ocular Therapeutix, Inc. (OCUL) Q3 2024 Earnings Call Transcript
Ocular Therapeutix, Inc. (OCUL) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
3 weeks ago
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.51 per share a year ago.
Neutral
GlobeNewsWire
3 weeks ago
Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV
BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced upcoming presentations at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV.
Neutral
GlobeNewsWire
4 weeks ago
Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024
BEDFORD, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it plans to host a conference call and webcast on Thursday, November 14, 2024, at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024.
Neutral
GlobeNewsWire
1 month ago
Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD
SOL-1 is now expected to be enrolled and fully randomized by year-end 2024 Topline clinical data from SOL-1 are now expected in Q4 2025 BEDFORD, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced accelerated timelines for the SOL-1 Phase 3 registrational clinical trial of AXPAXLI in wet age-related macular degeneration (wet AMD).
Positive
Zacks Investment Research
1 month ago
Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?
Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Neutral
Seeking Alpha
1 month ago
Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors
In my previous article, I rated Ocular as a “Hold” based on concerns regarding Axpaxli's path to market. The SOL-1 and SOL-R Phase III trials are designed to assess Axpaxli's safety, efficacy, and potential market disruption in wet-AMD treatment. OCUL's Elutyx drug delivery platform offers sustained long-term effects, making it a valuable asset beyond current retina-focused applications.
Neutral
GlobeNewsWire
1 month ago
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it has agreed to grant inducement awards to its newly appointed Chief Legal Officer, Todd D.C. Anderman. The awards were made as inducements material to Mr. Anderman's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Charts implemented using Lightweight Charts™